COMUNICADO: European Foundation for the Study of Diabetes and Lilly Diabetes Partner on 6 Million Euro Commitment to Diabetes Resear

Actualizado 14/11/2016 7:00:41 CET

Announcement Coincides with World Diabetes Day

INDIANAPOLIS, Nov. 14, 2016 /PRNewswire/ -- The European Foundation for the Study of Diabetes (EFSD) and Lilly Diabetes are partnering on a three-year, 6 million euro commitment designed to drive new research and education to better support people with diabetes, the organizations announced today. The Foundation is a not-for-profit organization governed by the executive committee of the European Association for the Study of Diabetes (EASD). Lilly Diabetes is a business within Indianapolis-based Eli Lilly and Company .

EFSD, EASD and Lilly have partnered for years in seeking out solutions for people with diabetes, and the agreement announced today is a comprehensive commitment among the organizations. This collaboration provides a wide range of programmes and a prize, covering and recognizing diabetes research and education, with a special focus on the support of young scientists and clinicians in Europe. The collaboration will include the following:

Albert Renold Prize: This annual prize for outstanding achievements in research on the islets of Langerhans will be awarded during the annual EASD conference.

Robert Turner Course: Focused on clinical research in diabetes, this course offers young researchers the opportunity to be trained by an outstanding team from Oxford University on the basic requirements for clinical research.

Open Research Fund: As part of this major effort to combat diabetes each year, the EFSD/Lilly European Diabetes Research Programme will support areas of basic or clinical diabetes research.

Fellowship Programme: This programme will encourage innovative research in the fields of diabetes and its complications, and promote excellence in medical education.

Scientists Training Course: This course will promote emerging talents in the field of diabetes research, and foster diabetes research throughout the world, offering a hands-on, practical approach.

Nearly 415 million people around the world have diabetes, including an estimated 60 million across Europe, according to the International Diabetes Federation (IDF).

"EFSD is delighted that the strong collaboration with Lilly continues to thoroughly explore all areas of diabetes research. Diabetes is one of the defining health problems of the 21st century, and, despite the great efforts being made, it still remains insufficiently understood," commented Professor Juleen Zierath, President of EASD/EFSD.

"Research for prevention, care and a cure is the only way to save lives and improve the well-being of the incredible number of people with diabetes in the world," said Professor Stefano Del Prato, chairman of EFSD. "EFSD supports the most dynamic research in diabetes in collaboration with industry and strives across the European Region to keep diabetes and research into this devastating chronic disease under continuous focus. The program just launched with the support of Lilly is another step forward to link science, research and education, and to attract younger investigators in a very competitive field."

"Our commitment to people with diabetes started more than 90 years ago when we partnered with the University of Toronto to deliver the first insulin to people with diabetes," said Jeremy Morgan, vice president of Lilly's international diabetes business. "And while there have been tremendous advancements in treatment options and awareness, gaps remain. Millions of people with diabetes are not treated adequately and, in some cases, are not even aware they have diabetes. We are looking forward to this new collaboration working hand-in-hand with EFSD to continue the important work dedicated to bridging these gaps."

"With this new collaboration, we aim to further strengthen the private-public collaboration in the research field and to make a contribution to top-quality education," said Robert Heine, M.D., Ph.D., Distinguished Lilly Scholar, Lilly Diabetes.

This enhanced commitment coincides with World Diabetes Day, which was created in 1991 by IDF and the World Health Organization in response to growing concerns about the escalating health threat posed by diabetes. World Diabetes Day became an official United Nations Day in 2006 with the passage of United Nation Resolution 61/225, and occurs annually on Nov. 14.

About EFSDThe European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding in all areas of diabetes research across the entire European Region. The aims of EFSD are to encourage and support groundbreaking diabetes research and to promote the next generation of leading diabetes researchers. More information about EFSD can be found at: []

About EASDThe European Association for the Study of Diabetes (EASD) was founded in 1965 and is based in Duesseldorf, Germany. It is one of the largest networks for diabetologists worldwide with the mission to promote excellence in diabetes care through research and education. EASD membership is open to health care professionals, scientists and nurses as well as students from all over the world who are interested in the field of diabetes. More information about EASD can be found at: []

About Lilly DiabetesLilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions--from medicines to support programs and more--we strive to make life better for all those affected by diabetes around the world. For more information, visit [] or follow us on Twitter: @LillyDiabetes.

About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at [] and [].

Refer to: Simon Mueller;;

+49 211 758 469 0; EASD

Jennifer Hoopingarner;;

317-741-8811; Lilly Diabetes

Logo -- []

Web site:

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación